Conditional sentence

Fujifilm Receives 510(k) Clearance for CAD EYE®, New AI-Powered Endoscopic Imaging Technology for Colonic Polyp Detection

Retrieved on: 
Wednesday, March 20, 2024
Colonoscopy, LCI, Documentation, Adenoma, EYE, Colorectal cancer, Conditional sentence, Risk, White Light, Polyp, APC, Assist, AI, Woman, Workflow, System, Safety, Swedish Health Services, Endoscopy, FDA, Health, CAD, Medical device

Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.

Key Points: 
  • Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.
  • CAD EYE® enables real-time detection of colonic mucosal lesions such as polyps and adenomas during colonoscopy procedures, supporting endoscopists in their ability to detect and remove pre-cancerous lesions, regardless of size, shape and color.
  • Consisting of a compatible expansion unit (the Fujifilm EX-1) and endoscopy support software (EW10-EC02), CAD EYE is an evolution of Fujifilm’s ELUXEO® Endoscopic Imaging System, featuring AI image processing functionality customized for the integration with the system’s processor and the endoscope.
  • CAD EYE, ELUXEO and LCI are registered trademarks of FUJIFILM Corporation in various jurisdictions.

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

Retrieved on: 
Wednesday, March 20, 2024
Tendinopathy, Artificiality, Health, Patient, Conditional sentence, History, Artificial intelligence, Lantern, Mantle cell lymphoma, OTCQX, Microsoft HoloLens, Context, Corporation, NEO, Microsoft, Automation, MCL, DHL, Splenic infarction, Diabetes, Risk, PALM, Radiology, Software, Treatment, UiPath, OTCQB, Strategic alliance, Prevalence, Disease, Microsoft Mesh, Hospital, Research, News, WELL, Student, TSX, MPH, Nursing, Machine learning, Diagnosis, TED (conference), OSCE, Growth, Cancer, Trust, Sarcoma, NHL, Appendicitis, Ecosystem, Probability, AIDX, Medical device

A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.

Key Points: 
  • A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.
  • MarketsAndMarkets continued: “Based on component, the AI in medical diagnostics market is bifurcated into software, services, and hardware.
  • The software segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.
  • The hospitals segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

Retrieved on: 
Tuesday, March 19, 2024
Conditional sentence, History, GI, Therapy, Drug development, Inflammatory bowel disease, FDA, Autoimmunity, Pharmaceutical industry

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.

Key Points: 
  • WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.
  • Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics.
  • Of particular relevance to Morphic as we advance MORF-057, is Simon’s experience in the development and approvals for therapeutically effective and commercially successful autoimmune and inflammatory agents in the GI space,” commented Praveen Tipirneni, Chief Executive Officer of Morphic.
  • I am also excited about the prospects for Morphic research programs for small molecules against non-integrin immunology targets and am looking forward to working with the Morphic Team,” commented Dr. Cooper.

The Institute for Functional Medicine Announces its 2024 Annual International Conference (AIC) - Repair, Restore, Regenerate: Healing of the Micro and the Macro Through Functional Medicine

Retrieved on: 
Tuesday, March 19, 2024
ANA, Health, Functional medicine, Conditional sentence, Conference, Q&A, Patient, Knowledge, Mental health, Research, Doctor of Philosophy, MD, Student, Outline, Pediatrics, American Nutrition Association, Bellagio (resort), Medicine, AIC

FEDERAL WAY, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- The Institute for Functional Medicine (IFM) is thrilled to announce its 2024 Annual International Conference (AIC), Repair, Restore, Regenerate: Healing of the Micro and the Macro Through Functional Medicine happening May 29 – June 1, 2024, at the Bellagio Resort & Casino in Las Vegas, NV.

Key Points: 
  • FEDERAL WAY, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- The Institute for Functional Medicine (IFM) is thrilled to announce its 2024 Annual International Conference (AIC), Repair, Restore, Regenerate: Healing of the Micro and the Macro Through Functional Medicine happening May 29 – June 1, 2024, at the Bellagio Resort & Casino in Las Vegas, NV.
  • A limited livestream will also be available to ensure healthcare providers from all care settings can discover new ways to support patient health and healing.
  • As the largest functional medicine event of the year, AIC brings together experts from all medical disciplines to review advancements in clinical research and explore new perspectives for delivering transformative care.
  • Other curated sessions will include lectures on pediatrics and preconception care and functional medicine foundational concepts and applications.

Rimidi Launches New Partnership Program, The Rimidi Care Network, to Increase Access to Remote Monitoring Services

Retrieved on: 
Tuesday, March 19, 2024
CGM, Conditional sentence, Remote patient monitoring, Communication, Partnership, Patient, Hospital, Doctor of Philosophy, MD, BHI, Chronic care management, CCM, EHR, Medicare, RPM, Health, RTM, Plague, Nursing

As a result, the new partnership program makes it easier for providers to expand the bandwidth of their staff and scale remote monitoring programs.

Key Points: 
  • As a result, the new partnership program makes it easier for providers to expand the bandwidth of their staff and scale remote monitoring programs.
  • “With The Rimidi Care Network, we can extend access to remote clinical monitoring services for healthcare providers and ultimately help them improve engagement outcomes for patients with chronic conditions.”
    Founding Rimidi Care Network Partners include:
    GatewayMD – a turnkey RPM, CCM, and BHI servicing and management company that enhances chronic disease management between patients and their providers, including Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) services.
  • Quest Health Services RPM – an industry-leading remote patient monitoring program and solution designed to offer the best experience possible for healthcare workers and patients, specializing in continuous glucose monitoring.
  • To learn more about The Rimidi Care Network and how to implement remote monitoring services into your practice, or for additional information on becoming a partner, visit rimidi.com/lp/rimidi-care-network .

AAFA Statement in Response to AstraZeneca Asthma Inhaler Cost Announcement

Retrieved on: 
Monday, March 18, 2024
AAFA, Conditional sentence, AstraZeneca, White, Patient, Research, Asthma, Ecosystem, Access, Death, Government, Human, Medicine, Pharmaceutical industry

Washington, DC, March 18, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) welcomes efforts to make asthma medicines more affordable and accessible.

Key Points: 
  • Washington, DC, March 18, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) welcomes efforts to make asthma medicines more affordable and accessible.
  • AAFA continues to lead advocacy efforts to change the drug pricing ecosystem on behalf of the 27 million people in the United States with asthma.
  • "AAFA applauds AstraZeneca’s announcement to cap costs of asthma inhalers and urges other manufacturers to take similar steps to make medications more affordable and accessible,” said AAFA President and CEO Kenneth Mendez.
  • AAFA’s research indicates that when the cost of medicine becomes a barrier to treatment , people with asthma resort to rationing or simply discontinue use.

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Retrieved on: 
Friday, March 15, 2024
Nosebleed, Research, Polyp (medicine), Vanderbilt University, Sciatica, Fluticasone, Education, Drainage, Disease, Incidence, Headache, Inflammation, Patient, Conditional sentence, Chronic obstructive pulmonary disease, Sinusitis, CRS, Standard of care, Quality of life, Migraine, Nasal cavity, Ear, ENT, Service, MPH, Nose, OPTN, FDA, Frustration, Food, Pharmaceutical industry

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

Key Points: 
  • Chronic sinusitis (also called “chronic rhinosinusitis” or “CRS”) is one of the most common chronic diseases, affecting approximately 30 million adults in the United States.
  • Research shows that the disease impairs quality of life to a similar degree as other serious chronic conditions, such as chronic obstructive pulmonary disease, sciatica, or migraine.
  • Chronic sinusitis is also one of the most common diagnoses in adult outpatient medicine.
  • Chronic sinusitis is diagnosed in approximately 10 million outpatient visits, of which approximately 70% result in antibiotic prescriptions, and leads to more than 600,000 surgeries annually.

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

Retrieved on: 
Friday, March 15, 2024
Health, Sleep apnea, Conditional sentence, Obesity, Exercise, RMD, ResMed, Somnolence, SAN, Insomnia, Social media, Sleep, ASX, News, Female, Irritation, Woman, Periodic breathing, COPD, Nursing

More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality.

Key Points: 
  • More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality.
  • SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases, today announced the results of its 2024 Global Sleep Survey in conjunction with World Sleep Day (March 15), shedding light on the critical sleep challenges faced by people around the world.
  • To learn more about ResMed’s 2024 Global Sleep Survey or for help identifying if you have symptoms that could indicate poor sleep health, visit https://www.resmed.com/sleepassessment .
  • The 2024 ResMed Global Sleep Survey included a total of 36,000 respondents across 17 markets including Australia, Brazil, China, France, Germany, Hong Kong, India, Ireland, Japan, Korea, Mexico, New Zealand, Singapore, Taiwan, Thailand, UK and USA, between December 2023 and January 2024.

Report: Climate Change Makes Living with Allergies a Challenge

Retrieved on: 
Thursday, March 14, 2024
AAFA, Climate change, Season, Post-nasal drip, Asthma, City, Pollen, Allergy, Air pollution, Allergen, Conditional sentence, Hospital, Cochineal

The top 20 Allergy Capitals™ for 2024 are:

Key Points: 
  • The top 20 Allergy Capitals™ for 2024 are:
    This year’s report again calls attention to the urgency of the climate crisis.
  • Due to climate change, growing seasons start earlier and last longer than they did just 30 years ago.
  • “Climate change fuels a perfect storm of conditions that make allergy season worse for people with pollen allergy,” said AAFA President and CEO Kenneth Mendez.
  • “Allergies are a common asthma trigger and lead to increased hospital visits for asthma during peak pollen seasons.”
    For information on preventing and treating allergies and asthma, visit aafa.org .

Uplifting Memoir UNPREDICTABLE Chronicles Abuse Recovery, Courage Through Faith

Retrieved on: 
Thursday, March 14, 2024
Honey, Perseverance, Abuse, Darkness, Domestic violence, Collection, Trauma, Survivor, Cancer, Conditional sentence

Two battles with cancer, surviving eighty-nine surgeries, and processing a childhood filled with every kind of abuse, she has built a successful and deeply fulfilling life.

Key Points: 
  • Two battles with cancer, surviving eighty-nine surgeries, and processing a childhood filled with every kind of abuse, she has built a successful and deeply fulfilling life.
  • Her true story is recounted in her memoir, Unpredictable: The walk in and out of darkness, a brand new title launched this fall by Palmetto Publishing.
  • The book was written to reach those who have faced chronic illness, other serious health conditions, domestic violence, and childhood trauma.
  • More than anything, she believes she was able to heal as a result of her faith.